source
- Scancell to list on Nasdaq after reverse merger with Neuphoria, funds $89M for melanoma immunotherapy trialScancell announced that it will become a publicly traded company on Nasdaq after completing an all‑stock reverse merger with Neophobia Therapeutics. The transaction gives Scancell a new ticker, SCL…
- Most FDA-approved drugs meet postmarketing study requirements, and advisory panel backs two peptides for bulk compoundingA recent analysis published in JAMA Network Open found that nearly nine out of ten drugs approved by the U.S. Food and Drug Administration have completed their postmarketing requirements or commitm…